These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25786447)

  • 21. [Antitubercular drug-induced liver injuries].
    Guo Y; Cui D
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):308-9. PubMed ID: 11326960
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.
    Bliven EE; Podewils LJ
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1054-60. PubMed ID: 19723392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of latent tuberculosis infection.
    Parekh MJ; Schluger NW
    Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
    Devrim İ; Devrim F; Bayram N; Aktürk H; Aksay A; Can D; Apa H
    Minerva Pediatr (Torino); 2021 Apr; 73(2):184-187. PubMed ID: 26377643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of isoniazid-induced liver injury diagnosed by use of the DLST, and successful reintroduction of isoniazid for pleural tuberculosis.
    Ikegame S; Wakamatsu K; Fujita M; Nakanishi Y; Kajiki A
    J Infect Chemother; 2011 Aug; 17(4):530-3. PubMed ID: 21188445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR; Trajman A; Cook VJ; Johnston JC; Adjobimey M; Ruslami R; Eisenbeis L; Fregonese F; Valiquette C; Benedetti A; Menzies D
    Lancet Infect Dis; 2020 Mar; 20(3):318-329. PubMed ID: 31866327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL; Goldberg HF
    Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
    Ziakas PD; Mylonakis E
    Clin Infect Dis; 2009 Dec; 49(12):1883-9. PubMed ID: 19911936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatal Isoniazid Hepatotoxicity in the Deployed Environment.
    Cybulski DJ; White BK
    Mil Med; 2021 May; 186(5-6):619-622. PubMed ID: 33128555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isoniazid-induced acute hepatitis and acute pancreatitis in a patient during chemoprophylaxis.
    Jin CF; Sable R
    J Clin Gastroenterol; 2002 Jul; 35(1):100-1. PubMed ID: 12080238
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of Rifampin Compared with Isoniazid for the Treatment of Latent Tuberculosis Infection in Japan: A Bayesian Inference with Markov Chain Monte Carlo Method.
    Iwata K; Morishita N; Nishiwaki M; Miyakoshi C
    Intern Med; 2020 Nov; 59(21):2687-2691. PubMed ID: 32669488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability of rifampin monotherapy for latent tuberculosis infection in children.
    Daskalaki I; Byun J; Dogbey MC; Tolbert-Warren C; Watson BM
    Pediatr Infect Dis J; 2011 Nov; 30(11):1014-5. PubMed ID: 21997666
    [No Abstract]   [Full Text] [Related]  

  • 35. Adverse events associated with treatment of latent tuberculosis in the general population.
    Smith BM; Schwartzman K; Bartlett G; Menzies D
    CMAJ; 2011 Feb; 183(3):E173-9. PubMed ID: 21220436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
    Nolan CM; Goldberg SV; Buskin SE
    JAMA; 1999 Mar; 281(11):1014-8. PubMed ID: 10086436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(8):224-9. PubMed ID: 20203555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.
    Ronald LA; FitzGerald JM; Bartlett-Esquilant G; Schwartzman K; Benedetti A; Boivin JF; Menzies D
    Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31980498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Isoniazid-inducedtoxic hepatitis].
    Kristensen KL; Nordholm AC; Clausen MR; Katzenstein TL
    Ugeskr Laeger; 2021 Feb; 183(6):. PubMed ID: 33570026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of isoniazid-related hepatotoxicity during chemoprophylaxis.
    Stuart RL; Grayson ML
    Aust N Z J Med; 1999 Jun; 29(3):362-7. PubMed ID: 10868500
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.